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Worldwide ~235 million people currently suffer from
asthma. We searched the integrative medicine and the
ancient cultures in the Middle East, Africa, and China for
new anti-asthma treatment. LE25-0712 is an herbal extract
(formula under patent). Here, we used it to validate the
old knowledge known, to treat acute allergic asthma mice
model. We also identify the effect of our novel extract on
the expression of AMs-HDAC1 (alveolar macrophages-
histone deacetylase1). We had proven in a previous study,
deletion of HDAC1 had increased allergic airway inflam-
mation and enhanced Th2 cytokine production in asthma
mice model. In asthmatic and COPD patients, PBMC-
HDAC level was reduced compared to healthy individual.
In this study, we evaluated the effect of LE25-0712 on the
expression level of AMs-HDAC1 in treated asthmatic
mice (TAM) model compared to asthmatic control (AC)
group.
Methods
We used the acute asthma model of C57BL/6 mice, i.p.
sensitized and i.n. challenged on d28, 29 with (OVA).
LE25-0712 (0.5 mg/kg) was i.n. administered b.i.d (d25-
29). WE assayed bronchoalveolar lavage fluid (BALF) for
the total and differential types of inflammatory cells, and
the expression of HDAC1 by IMF (d31). Näive and AC
groups were included. As LE25-712 is a safe herbal supple-
ment, allergic asthma patients were treated b.i.d by it com-
bined with corticosteroid, until complete replacement of
steroid.
Results
LE25-0712 treatment of TAM group resulted in signifi-
cant anti-inflammatory and anti- allergic activity as
shown by reduced BAL total leukocytes (P < 0.03), and
reduced eosinophils (P < 0.002) compared to the AC
group. The expression of HDAC1 in AMs-näive was
(87%), which was decreased in CA group to (8%). LE25-
0712 restores HDAC1 expression in AMs of treated
asthma model (45%, P < 0.0001). In 15 chronic asth-
matic patients, LE25-0712 exerts a dramatic improve-
ment in the general condition in 100% of patients, as it
relieves the obstructive airway condition, which leads to
complete spare of corticosteroids administration.
Conclusion
The novel LE25-0712 is an effective natural safe medic-
inal extract for the prophylaxis of acute asthma disease
in mice, as well as controlling the recurrent asthmatic
attacks in chronic patients. The effectiveness and safety
administration of this extract give it the upper hand
over the traditional corticosteroid treatment. Moreover
it restores the HDAC1 expression in TAM groups,
which can be used as a follow up marker.
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